News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,177 Results
Type
Article (46818)
Company Profile (295)
Press Release (674064)
Multimedia
Podcasts (66)
Webinars (12)
Section
Business (209270)
Career Advice (2189)
Deals (36019)
Drug Delivery (114)
Drug Development (82358)
Employer Resources (191)
FDA (16359)
Job Trends (15252)
News (352652)
Policy (33255)
Tag
Academia (2743)
Academic (2)
Accelerated approval (5)
Adcomms (23)
Allergies (87)
Alliances (50999)
ALS (92)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (131)
Approvals (16358)
Artificial intelligence (277)
Autoimmune disease (22)
Automation (16)
Bankruptcy (366)
Best Places to Work (11826)
BIOSECURE Act (20)
Biosimilars (107)
Biotechnology (201)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (281)
Cancer (2291)
Cardiovascular disease (180)
Career advice (1837)
Career pathing (33)
CAR-T (161)
Cell therapy (445)
Cervical cancer (20)
Clinical research (66720)
Collaboration (861)
Company closure (1)
Compensation (534)
Complete response letters (21)
COVID-19 (2668)
CRISPR (42)
C-suite (249)
Cystic fibrosis (101)
Data (2218)
Decentralized trials (2)
Denatured (31)
Depression (44)
Diabetes (272)
Diagnostics (6522)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (123)
Drug pricing (108)
Drug shortages (26)
Duchenne muscular dystrophy (96)
Earnings (87503)
Editorial (40)
Employer branding (25)
Employer resources (161)
Events (115959)
Executive appointments (741)
FDA (17634)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (778)
Gene editing (109)
Generative AI (22)
Gene therapy (319)
GLP-1 (758)
Government (4570)
Grass and pollen (4)
Guidances (67)
Healthcare (19197)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (122)
Indications (29)
Infectious disease (2813)
Inflammatory bowel disease (142)
Inflation Reduction Act (10)
Influenza (51)
Intellectual property (98)
Interviews (345)
IPO (16718)
IRA (42)
Job creations (3842)
Job search strategy (1570)
Kidney cancer (10)
Labor market (41)
Layoffs (490)
Leadership (19)
Legal (8069)
Liver cancer (76)
Lung cancer (328)
Lymphoma (155)
Machine learning (7)
Management (62)
Manufacturing (315)
MASH (69)
Medical device (13533)
Medtech (13538)
Mergers & acquisitions (19847)
Metabolic disorders (709)
Multiple sclerosis (82)
NASH (22)
Neurodegenerative disease (93)
Neuropsychiatric disorders (27)
Neuroscience (1978)
NextGen: Class of 2025 (6717)
Non-profit (4650)
Now hiring (40)
Obesity (383)
Opinion (224)
Ovarian cancer (77)
Pain (90)
Pancreatic cancer (84)
Parkinson's disease (152)
Partnered (21)
Patents (236)
Patient recruitment (114)
Peanut (48)
People (59305)
Pharmaceutical (71)
Pharmacy benefit managers (18)
Phase I (20785)
Phase II (29365)
Phase III (21886)
Pipeline (1210)
Policy (144)
Postmarket research (2643)
Preclinical (9066)
Press Release (72)
Prostate cancer (107)
Psychedelics (32)
Radiopharmaceuticals (252)
Rare diseases (386)
Real estate (6228)
Recruiting (72)
Regulatory (22729)
Reports (55)
Research institute (2477)
Resumes & cover letters (374)
Rett syndrome (5)
RNA editing (5)
RSV (44)
Schizophrenia (73)
Series A (138)
Series B (87)
Service/supplier (14)
Sickle cell disease (55)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3779)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (40)
The Weekly (33)
Vaccines (718)
Venture capitalists (43)
Weight loss (253)
Women's health (37)
Worklife (18)
Date
Today (158)
Last 7 days (939)
Last 30 days (2669)
Last 365 days (33354)
2025 (10933)
2024 (35947)
2023 (40860)
2022 (51924)
2021 (56499)
2020 (54898)
2019 (47645)
2018 (35937)
2017 (33086)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30535)
2010 (29032)
Location
Africa (793)
Alabama (54)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39525)
Australia (6502)
California (6202)
Canada (2024)
China (531)
Colorado (274)
Connecticut (275)
Delaware (149)
Europe (85924)
Florida (917)
Georgia (215)
Hawaii (1)
Idaho (58)
Illinois (553)
India (27)
Indiana (317)
Iowa (11)
Japan (163)
Kansas (106)
Kentucky (26)
Louisiana (11)
Maine (62)
Maryland (909)
Massachusetts (4649)
Michigan (238)
Minnesota (409)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (65)
New Jersey (1751)
New Mexico (30)
New York (1772)
North Carolina (1011)
North Dakota (9)
Northern California (2703)
Ohio (206)
Oklahoma (14)
Oregon (34)
Pennsylvania (1388)
Puerto Rico (12)
Rhode Island (33)
South America (1171)
South Carolina (23)
South Dakota (1)
Southern California (2323)
Tennessee (102)
Texas (920)
United States (23529)
Utah (185)
Virginia (148)
Washington D.C. (67)
Washington State (559)
West Virginia (3)
Wisconsin (65)
721,177 Results for "roivant sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
April 21, 2025
·
11 min read
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
M&A
Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
September 18, 2024
·
3 min read
·
Annalee Armstrong
Press Releases
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
March 19, 2025
·
13 min read
Press Releases
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
February 10, 2025
·
17 min read
Drug Development
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung).
April 25, 2024
·
6 min read
Press Releases
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
March 18, 2025
·
1 min read
Press Releases
Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development
January 13, 2025
·
2 min read
Press Releases
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
January 30, 2025
·
4 min read
Business
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.
May 30, 2024
·
21 min read
1 of 72,118
Next
